Comparative Pharmacology
Head-to-head clinical analysis: PHENERGAN VC versus TELDRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PHENERGAN VC versus TELDRIN.
PHENERGAN VC vs TELDRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phenergan VC is a combination of promethazine (a phenothiazine derivative with antihistaminic, sedative, antiemetic, and anticholinergic effects) and phenylephrine (a sympathomimetic amine that acts as a decongestant via alpha-1 adrenergic receptor agonism). Promethazine antagonizes H1 receptors, thereby suppressing allergic reactions and motion sickness. Phenylephrine causes vasoconstriction in the nasal mucosa, reducing congestion.
TELDRIN contains loratadine and pseudoephedrine. Loratadine is a long-acting tricyclic antihistamine with selective peripheral H1-receptor antagonism. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction.
10-20 mL orally every 4-6 hours as needed; each 5 mL contains 6.25 mg promethazine HCl and 5 mg phenylephrine HCl.
1-2 mg orally twice daily; maximum 4 mg/day.
None Documented
None Documented
9-16 hours; prolonged in hepatic impairment.
Terminal half-life: 9-12 hours (range 8-14) in healthy adults; prolonged in renal impairment.
Renal: 70-80% as metabolites; biliary/fecal: 20-30%.
Renal: 55-60% unchanged; fecal: 35-40%; minor biliary elimination.
Category C
Category C
Antihistamine/Decongestant Combination
Antihistamine